Oxycodone
drugOn this page
Also known as DihydroneIDS-NO-002N02AA05NSC-19043OxicodonaOxiconeOxycodone ciiPavinalPF-00345439ProladonePti 821PTI-821RemoxyXtampzaXtampza er
Summary
Oxycodone (CHEMBL656) is an approved small-molecule opioid analgesic (ATC N02AA05); indicated across 36 conditions including substance-related disorder and drug dependence.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: N02AA05
- Indications: 36 conditions
- Clinical trials: 295
- Chemistry: 315.4 Da · C18H21NO4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL656 |
| Name | Oxycodone |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5284603 |
| ChEBI | CHEBI:7852 |
| ATC | N02AA05 |
| Molecular formula | C18H21NO4 |
| Molecular weight | 315.4 |
| InChIKey | BRUQQQPBMZOVGD-XFKAJCMBSA-N |
SMILES: CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
IUPAC name: (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
ChEBI definition: A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.
Pharmacological roles (ChEBI): opioid analgesic, μ-opioid receptor agonist, antitussive.
Also known as: Dihydrone, IDS-NO-002, N02AA05, NSC-19043, Oxicodona, Oxicone, Oxycodone, Oxycodone cii, Pavinal, PF-00345439, Proladone, Pti 821
Parent form; salt/anhydrous children: CHEMBL1200890, CHEMBL3989826
Patent coverage: 12,897 distinct patent families (52,245 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 52,145 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Mu-type opioid receptor, Delta-type opioid receptor, Kappa-type opioid receptor, Delta-type opioid receptor, Mu-type opioid receptor, Mu-type opioid receptor, Kappa-type opioid receptor, Kappa-type opioid receptor, Acetylcholinesterase, Kappa-type opioid receptor.
Bioactivity
ChEMBL activities: 20 potent at pChembl ≥ 5 of 24 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P33535 | 8.05 | Ki | 8.9 | nM | CHEMBL_ACT_19067517 |
| OPRM1 | 7.92 | Ki | 12 | nM | CHEMBL_ACT_19055856 |
| OPRM1 | 7.92 | Ki | 12 | nM | CHEMBL_ACT_22431576 |
| OPRM1 | 7.92 | Ki | 12 | nM | CHEMBL_ACT_24356595 |
| OPRM1 | 7.77 | EC50 | 17 | nM | CHEMBL_ACT_19055913 |
| OPRM1 | 7.77 | EC50 | 17 | nM | CHEMBL_ACT_22431547 |
| OPRM1 | 7.77 | EC50 | 17 | nM | CHEMBL_ACT_24356641 |
| P33535 | 7.6 | EC50 | 25 | nM | CHEMBL_ACT_19067695 |
| P33535 | 7.36 | Ki | 43.6 | nM | CHEMBL_ACT_1485564 |
| OPRM1 | 6.88 | Ki | 133.5 | nM | CHEMBL_ACT_17744417 |
| P42866 | 6.8 | EC50 | 160 | nM | CHEMBL_ACT_13437592 |
| OPRM1 | 6.64 | AC50 | 230 | nM | CHEMBL_ACT_25147119 |
| P41144 | 6.49 | Ki | 325 | nM | CHEMBL_ACT_19067551 |
| OPRM1 | 6.32 | EC50 | 478 | nM | CHEMBL_ACT_17744471 |
| P33533 | 6.31 | Ki | 487 | nM | CHEMBL_ACT_19067534 |
| OPRM1 | 6.3 | EC50 | 500 | nM | CHEMBL_ACT_13437588 |
| P33533 | 5.96 | Ki | 1087 | nM | CHEMBL_ACT_1485565 |
| OPRK1 | 5.7 | AC50 | 2000 | nM | CHEMBL_ACT_25129735 |
| P34975 | 5.58 | Ki | 2658 | nM | CHEMBL_ACT_1485566 |
| OPRD1 | 5.4 | EC50 | 4000 | nM | CHEMBL_ACT_13437564 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
36 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| substance-related disorder | 4 | MONDO:0002494 | MONDO:0002491 |
| drug dependence | 4 | MONDO:0005303 | EFO:0003890 |
| osteoarthritis, knee | 3 | MONDO:0005416 | EFO:0004616 |
| restless legs syndrome | 3 | MONDO:0005391 | EFO:0004270 |
| arthropathy | 3 | MONDO:0006816 | EFO:1000999 |
| nephrolithiasis | 3 | MONDO:0008171 | EFO:0004253 |
| diabetic neuropathy | 3 | MONDO:0006626 | MONDO:0001583 |
| hypospadias | 3 | MONDO:0005345 | EFO:0004209 |
| osteoarthritis, hip | 3 | MONDO:0006629 | EFO:1000786 |
| female reproductive organ cancer | 3 | MONDO:0001416 | EFO:1001331 |
| osteoarthritis | 3 | MONDO:0005178 | MONDO:0005178 |
| Parkinson disease | 3 | MONDO:0005180 | MONDO:0005180 |
| neoplasm | 3 | MONDO:0005070 | MONDO:0004992 |
| opiate dependence | 2 | MONDO:0005530 | EFO:0005611 |
| neuralgia | 2 | MONDO:0021667 | EFO:0005762 |
| sinusitis | 2 | MONDO:0005961 | EFO:0007486 |
| preeclampsia | 2 | MONDO:0005081 | EFO:0000668 |
| nutritional disorder | 2 | MONDO:0005137 | EFO:0001069 |
| spinal cord injury | 2 | MONDO:0043797 | EFO:1001919 |
| kidney cancer | 2 | MONDO:0002367 | MONDO:0002367 |
| kidney neoplasm | 2 | MONDO:0021163 | EFO:0003865 |
| respiratory failure | 1 | MONDO:0021113 | EFO:0009842 |
| intervertebral disk degenerative disorder | 1 | MONDO:0011385 | HP:0008419 |
| depressive disorder | 1 | MONDO:0002050 | MONDO:0002050 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
| head and neck cancer | 0 | MONDO:0005627 | EFO:0006859 |
10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 295.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 109 |
| Not specified | 53 |
| PHASE3 | 50 |
| PHASE1 | 35 |
| PHASE2 | 29 |
| EARLY_PHASE1 | 11 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02044497 | PHASE4 | ACTIVE_NOT_RECRUITING | Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients |
| NCT03054831 | PHASE4 | ACTIVE_NOT_RECRUITING | The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric |
| NCT03759028 | PHASE4 | RECRUITING | Supracondylar Post-Operative Pain Study |
| NCT05076110 | PHASE4 | RECRUITING | Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures |
| NCT05488847 | PHASE4 | ACTIVE_NOT_RECRUITING | Opioid-Free Pain Protocol After Shoulder Arthroplasty |
| NCT06186141 | PHASE4 | RECRUITING | Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone |
| NCT06434233 | PHASE4 | RECRUITING | Opioid Use After Laparoscopic Salpingectomy |
| NCT06669650 | PHASE4 | ACTIVE_NOT_RECRUITING | Personalized Post-Operative Pain Management |
| NCT06897917 | PHASE4 | NOT_YET_RECRUITING | Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain |
| NCT07153003 | PHASE4 | ENROLLING_BY_INVITATION | Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty |
| NCT07219888 | PHASE4 | ENROLLING_BY_INVITATION | Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty |
| NCT07435077 | PHASE4 | NOT_YET_RECRUITING | Examining Analgesic Synergy and Efficacy in Trauma Care |
| NCT00027014 | PHASE4 | COMPLETED | Herb-Opioid Interactions |
| NCT00260260 | PHASE4 | COMPLETED | OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain |
| NCT00271973 | PHASE4 | COMPLETED | OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models |
| NCT00369811 | PHASE4 | COMPLETED | Oxycodone vs Fentanyl for Pain Treatment After Laparoscopic Cholecystectomy |
| NCT00414453 | PHASE4 | TERMINATED | Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis |
| NCT00480142 | PHASE4 | UNKNOWN | Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy |
| NCT00484718 | PHASE4 | TERMINATED | Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib. |
| NCT00499460 | PHASE4 | COMPLETED | Effects of Garlic Supplements on Opioids in Healthy Volunteers |
| NCT00528177 | PHASE4 | COMPLETED | Morphine vs. Oxycodone for Postoperative Pain Management |
| NCT00681174 | PHASE4 | TERMINATED | Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery |
| NCT00784810 | PHASE4 | COMPLETED | A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis |
| NCT00916890 | PHASE4 | SUSPENDED | Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain |
| NCT00964808 | PHASE4 | COMPLETED | Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur |
| NCT01083485 | PHASE4 | COMPLETED | OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty |
| NCT01109511 | PHASE4 | COMPLETED | A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy |
| NCT01313780 | PHASE4 | COMPLETED | A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients |
| NCT01344720 | PHASE4 | UNKNOWN | Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain |
| NCT01374763 | PHASE4 | COMPLETED | A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery |
| NCT01381120 | PHASE4 | COMPLETED | Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms |
| NCT01458015 | PHASE4 | TERMINATED | Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain |
| NCT01500317 | PHASE4 | COMPLETED | Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans |
| NCT01502644 | PHASE4 | COMPLETED | Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms |
| NCT01536301 | PHASE4 | COMPLETED | Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery |
| NCT01587274 | PHASE4 | COMPLETED | A Randomized Study of Three Medication Regimens for Acute Low Back Pain |
| NCT01672112 | PHASE4 | COMPLETED | Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain |
| NCT01719757 | PHASE4 | COMPLETED | PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain |
| NCT01809106 | PHASE4 | COMPLETED | RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder. |
| NCT01811186 | PHASE4 | COMPLETED | An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):
| Guideline | Source | Gene(s) | Dosing | Recommendation |
|---|---|---|---|---|
| Annotation of DPWG Guideline for oxycodone and CYP2D6 | DPWG | CYP2D6 | ||
| Annotation of CPIC Guideline for methadone, oxycodone and COMT, CYP2D6 | CPIC | COMT;CYP2D6;OPRM1 |
PharmGKB also curates 21 clinical and 126 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).